Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study
Citation
Ahmet Bilici, Mukremin Uysal, Serkan Menekse, Semih Akin, Fatih Yildiz, Merve Turan, Sema Sezgin Goksu, Ismail Beypinar, Teoman Sakalar, Mustafa Değirmenci, Dilek Erdem, Gul Basaran, Omer Fatih Olmez, Nilufer Avci, Deniz Tural, Abdullah Sakin, Sema Turker, Atakan Demir, Suleyman Temiz, Muhammed Ali Kaplan, Mutlu Dogan, Ozgur Tanriverdi, Irem Bilgetekin, Havva Yesil Cinkir, Ozgur Acikgoz, Semra Paydas, Ruchan Uslu & Serdar Turhal (2021): Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study, Cancer Investigation, DOI: 10.1080/07357907.2021.2017952Abstract
Purpose: This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) metastatic breast cancer (MBC) patients in real-life settings. Methods: Overall, 204 HR+, HER2− MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed. Results: The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024). The presence of bone-only metastasis was associated with better treatment response (p = 0.002), PFS (p < 0.001), and OS (p = 0.001). Conclusion: We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER − MBC patients.
